$BCRX

6 stories mentioning BCRXUpdated 3d ago

Every FINWIRES story that references BCRX, newest first.

What are analysts saying about BCRX?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on BCRX?

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.5%.The iShares Biotechnology ETF (IBB) dropped 1.4%.In corporate news, Cooper (COO) shares fell past 13% after the company cut its fiscal 2026 guidance. Separately, BofA Securities downgraded Cooper to neutral from buy and lowered its price target to $65 from $80. BofA said Cooper could not sell CooperSurgical at an attractive valuation given competition from the Paragard intrauterine device and the fertility litigation settlement.Novartis (NVS) shareholder Artisan Partners called for changes to the Swiss drugmaker's board following two consecutive drug trial setbacks that sent shares tumbling, Reuters reported, citing an interview with Artisan managing director David Samra. Novartis shares were up 0.3%.Orchestra BioMed (OBIO) shares rose past 7% after BTIG upgraded the stock the stock to buy from neutral, with a price target of $10.BioCryst Pharmaceuticals' (BCRX) Ordaleyo faces competitive pressure in the hereditary angioedema treatment space, and its shares are expected to settle within an in-line trading range in the near term, RBC Capital Markets said in a note. RBC downgraded the company's stock rating to sector-perform from outperform and reduced the price target to $11 from $13. BioCryst shares fell 6%.

$BCRX$COO$NVS$OBIO

Wire3d ago

Sector Update: Healthcare Stocks Softer in Afternoon Trading

Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index shedding 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.The iShares Biotechnology ETF (IBB) dropped 1.2%.In corporate news, Cooper (COO) shares fell past 14% after the company cut its fiscal 2026 guidance. Separately, BofA Securities downgraded Cooper to neutral from buy and lowered its price target to $65 from $80. BofA said Cooper could not sell CooperSurgical at an attractive valuation given competition from the Paragard intrauterine device and the fertility litigation settlement.Novartis (NVS) shareholder Artisan Partners called for changes to the Swiss drugmaker's board following two consecutive drug trial setbacks that sent shares tumbling, Reuters reported, citing an interview with Artisan managing director David Samra. Novartis shares were up 0.4%.BioCryst Pharmaceuticals' (BCRX) Ordaleyo faces competitive pressure in the hereditary angioedema treatment space, and its shares are expected to settle within an in-line trading range in the near term, RBC Capital Markets said in a note. RBC downgraded the company's stock rating to sector-perform from outperform and reduced the price target to $11 from $13. BioCryst shares fell 6.1%.

$BCRX$COO$NVS

Wire3d ago

BioCryst Pharmaceuticals Faces Competitive Pressure in Hereditary Angioedema Treatment, RBC Says

BioCryst Pharmaceuticals' (BCRX) Ordaleyo faces competitive pressure in the hereditary angioedema treatment space, and its shares are expected to settle within an in-line trading range in the near term, RBC Capital Markets said in a Thursday note.Pharvaris' (PHVS) released stronger-than-expected data for deucrictibant XR, its competing oral agent for treating hereditary angioedema, and conversations with key opinion leaders revealed that more doctors may move patients from Ordaleyo to the rival offering than consensus numbers would imply, RBC analysts said.The analysts said they see Ordaleyo likely continuing to grow in the near term, but now project Ordaleyo's long-term annual revenue to drop to a range of $400 million to $450 million from their previous estimate of $500 million to $550 million.Meanwhile, the analysts said they are optimistic that BioCryst's long-acting injectable navenibart will drive a new phase of growth, clinical data is likely still a year away, and the launch of deucrictibant XR could limit how much the company's stock rises, even with quarterly beats.RBC downgraded the company's stock rating to sector-perform from outperform and reduced the price target to $11 from $13.Price: $8.11, Change: $-0.70, Percent Change: -7.95%

$BCRX$PHVS

Research3d ago

RBC Downgrades BioCryst Pharmaceuticals to Sector Perform From Outperform, Cuts Price Target to $11 From $13

BioCryst Pharmaceuticals (BCRX) has an average rating of buy and mean price target of $20.64, according to analysts polled by FactSet.

$BCRX

Wire39d ago

Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $20 From $21, Maintains Outperform Rating

BioCryst Pharmaceuticals (BCRX) has an average rating of Buy and mean price target of $21.90, according to analysts polled by FactSet.Price: $9.00, Change: $-0.03, Percent Change: -0.28%

$BCRX

Sectors93d ago

Sector Update: Healthcare Stocks Advance Pre-Bell Friday

Healthcare stocks were advancing pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% higher and the iShares Biotechnology ETF (IBB) up 0.3%.BeOne Medicines (ONC) stock was up more than 1% after the company said new data for tacabrutideg, a Bruton's tyrosine kinase degrader, showed "durable responses" in pretreated relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma patients and promising activity in BTK inhibitor-naive patients.BioCryst Pharmaceuticals' (BCRX) Orladeyo was associated with "early and sustained reductions" in hereditary angioedema or HAE attacks, demonstrated by new clinical data from the ongoing APeX-P study, the company said. BioCryst Pharmaceuticals shares were up 0.1% premarket.Rocket Pharmaceuticals (RCKT) stock was up nearly 2% after the company closed the $180 million sale of its rare pediatric disease priority review voucher.

$BCRX$IBB$ONC$RCKT$XLV

Track with the FINWIRES app suite

FolioX

Track BCRX in your portfolio

WheelAI

Analyze BCRX options with the wheel strategy

StockInsider

See market sentiment on BCRX